Study of T-DXd Monotherapy in Patients with HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma who have Received 2 or More Prior Regimens - DG-06

Study identifier:D9676C00002

ClinicalTrials.gov identifier:NCT04989816

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients with HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)

Medical condition

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase

Phase 2

Healthy volunteers

No

Study drug

Trastuzumab Deruxtecan

Sex

All

Actual Enrollment

95

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 20 Aug 2021
Primary Completion Date: 16 Jun 2023
Study Completion Date: 28 Feb 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Daiichi Sankyo Co., Ltd.

Inclusion and exclusion criteria